JP2014512363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512363A5 JP2014512363A5 JP2014504058A JP2014504058A JP2014512363A5 JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5 JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- masp
- mbl
- wallis
- letter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473698P | 2011-04-08 | 2011-04-08 | |
| US61/473,698 | 2011-04-08 | ||
| PCT/US2012/032650 WO2012139081A2 (en) | 2011-04-08 | 2012-04-06 | Methods for treating conditions associated with masp-2 dependent complement activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Division JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512363A JP2014512363A (ja) | 2014-05-22 |
| JP2014512363A5 true JP2014512363A5 (OSRAM) | 2014-09-11 |
| JP5937197B2 JP5937197B2 (ja) | 2016-06-22 |
Family
ID=46966283
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504058A Active JP5937197B2 (ja) | 2011-04-08 | 2012-04-06 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US8951522B2 (OSRAM) |
| EP (3) | EP2694108B1 (OSRAM) |
| JP (4) | JP5937197B2 (OSRAM) |
| KR (6) | KR20220044616A (OSRAM) |
| CN (3) | CN107638565B (OSRAM) |
| AU (1) | AU2012239889B2 (OSRAM) |
| BR (1) | BR112013025917A2 (OSRAM) |
| CA (4) | CA2832187C (OSRAM) |
| CL (1) | CL2013002874A1 (OSRAM) |
| DK (2) | DK3287142T3 (OSRAM) |
| ES (2) | ES2683307T3 (OSRAM) |
| IL (3) | IL228758B (OSRAM) |
| MX (3) | MX355648B (OSRAM) |
| NZ (5) | NZ731596A (OSRAM) |
| PL (1) | PL3287142T3 (OSRAM) |
| RU (2) | RU2662563C2 (OSRAM) |
| WO (1) | WO2012139081A2 (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0688182B2 (ja) | 1986-09-08 | 1994-11-09 | バブコツク日立株式会社 | スタツド着脱装置 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| CN107638565B (zh) | 2011-04-08 | 2021-12-21 | 莱斯特大学 | 用于治疗与masp-2依赖性补体活化相关的状况的方法 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| SMT201800253T1 (it) * | 2012-04-06 | 2018-07-17 | Omeros Corp | Composizioni e metodi per inibire masp-1 e/o masp-3 per il trattamento di emoglobinuria parossistica notturna |
| EP2861246B1 (en) * | 2012-06-18 | 2021-01-20 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| PL2914291T3 (pl) | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| AU2014229020B2 (en) * | 2013-03-15 | 2017-09-28 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| RS61351B1 (sr) * | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| HUE045646T2 (hu) | 2014-06-12 | 2020-01-28 | Ra Pharmaceuticals Inc | Komplement aktivitás modulálása |
| WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| PL3280440T3 (pl) | 2015-04-06 | 2023-06-19 | Bioverativ Usa Inc. | Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania |
| EA201891132A1 (ru) | 2015-11-09 | 2018-10-31 | Омерос Корпорейшн | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
| EP4218790B1 (en) | 2015-12-16 | 2026-02-18 | UCB Holdings, Inc. | Modulators of complement activity |
| AU2016375183B2 (en) * | 2015-12-23 | 2021-01-21 | eleva GmbH | Polypeptides for inhibiting complement activation |
| SG11201805695SA (en) * | 2016-01-05 | 2018-07-30 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| EA202191185A1 (ru) * | 2016-03-31 | 2021-10-29 | Омерос Корпорейшн | Способы ингибирования ангиогенеза у пациента |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| EP4652926A3 (en) | 2016-10-12 | 2026-03-18 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| JOP20190068B1 (ar) * | 2016-10-13 | 2024-12-22 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2018124132A1 (ja) * | 2016-12-26 | 2018-07-05 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
| JPWO2018164186A1 (ja) * | 2017-03-09 | 2020-01-09 | 協和キリン株式会社 | Ｍａｓｐ２の発現を抑制する核酸 |
| JP6967810B2 (ja) * | 2017-07-28 | 2021-11-17 | レモネックス インコーポレイテッドLemonex Inc. | 肝癌の予防または治療用の薬学的組成物 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN118236391A (zh) | 2017-12-01 | 2024-06-25 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| KR20200095485A (ko) | 2017-12-04 | 2020-08-10 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| CN118373875A (zh) | 2018-05-29 | 2024-07-23 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| EP3628735A1 (en) * | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| EA202191342A1 (ru) * | 2018-11-15 | 2021-08-10 | Айонис Фармасьютикалз, Инк. | Модуляторы экспрессии irf5 |
| CA3124730A1 (en) * | 2018-12-25 | 2020-07-02 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combinations thereof |
| CN112423794A (zh) | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3934675A2 (en) | 2019-03-08 | 2022-01-12 | RA Pharmaceuticals, Inc. | Zilucoplan as deep tissue penetrating c5 inhibitor |
| EP3981431A4 (en) * | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
| US20230115176A1 (en) | 2019-03-29 | 2023-04-13 | Ra Pharmaceuticals, Inc. | Complement Modulators and Related Methods |
| CA3137895A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| JP7663951B2 (ja) | 2019-05-22 | 2025-04-17 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| TWI863999B (zh) * | 2019-05-22 | 2024-12-01 | 大陸商蘇州瑞博生物技術股份有限公司 | ｓｉＲＮＡ綴合物、其用途及使用其之方法 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113811613B (zh) | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2020238766A1 (zh) | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US12558398B2 (en) | 2019-06-04 | 2026-02-24 | Ucb Holdings, Inc. | Inflammatory disease treatment with complement inhibitors |
| CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
| WO2021107057A1 (ja) | 2019-11-27 | 2021-06-03 | 京セラ株式会社 | 通信制御方法及びユーザ装置 |
| WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| KR20220110531A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| KR20220110529A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| WO2021113698A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2021168148A1 (en) * | 2020-02-19 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| EP4150338A1 (en) * | 2020-05-15 | 2023-03-22 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113674860B (zh) * | 2020-05-15 | 2024-05-17 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、系统及其应用 |
| IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN120173119B (zh) * | 2020-12-16 | 2025-09-30 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| EP4331603A4 (en) * | 2021-04-25 | 2025-04-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-MASP2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF |
| PY22106817A (es) | 2021-12-10 | 2023-12-21 | Omeros Corp | Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos |
| CA3262515A1 (en) * | 2022-07-25 | 2024-02-01 | Amgen Inc. | ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| WO2025076476A2 (en) | 2023-10-06 | 2025-04-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN119978131B (zh) * | 2025-04-15 | 2025-06-27 | 北京赛斯维德生物科技有限公司 | 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU632993B2 (en) | 1987-12-15 | 1993-01-21 | Gene Shears Pty. Limited | Ribozymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| BR9509985A (pt) | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solução para irrigação e método para inibição de dor inflamação e esparmo |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| CA2347734A1 (en) | 1998-12-15 | 2000-06-22 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| EP1200127B1 (en) | 1999-07-21 | 2008-06-25 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US20030186419A1 (en) | 1999-12-02 | 2003-10-02 | Jensenius Jens Christian | Masp-3, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| ATE434661T1 (de) | 2000-07-13 | 2009-07-15 | Helion Biotech Aps | Masp-2, ein komplement fixierendes enzym, und dessen verwendungen |
| JP2004536138A (ja) | 2001-07-26 | 2004-12-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 認識機能を改善する方法 |
| JP2005519917A (ja) | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | 軟骨分解の全身阻害のための組成物および方法 |
| WO2003081206A2 (en) | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| CA2490007C (en) | 2002-07-19 | 2011-05-24 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| CN103143022A (zh) | 2002-07-30 | 2013-06-12 | 奥默罗斯公司 | 眼科冲洗液及方法 |
| ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
| US20060275764A1 (en) | 2002-12-03 | 2006-12-07 | Aarhus Universitet | Method for determining predisposition to manifestation of immune system related diseases |
| EP1601377A4 (en) | 2003-02-21 | 2009-07-15 | Genentech Inc | METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE |
| CA2519258C (en) * | 2003-03-17 | 2014-04-22 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease |
| CN1798769A (zh) | 2003-05-12 | 2006-07-05 | 内蒂穆恩公司 | 抗masp－2抗体 |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2005123776A1 (en) | 2004-06-10 | 2005-12-29 | Omeros Corporation | Methods for treating conditions associated with lectin-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| EP2386315A1 (en) * | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2006257073B2 (en) * | 2005-06-17 | 2011-08-04 | Children's Medical Center Corporation | ADAMTS13-comprising compositions having thrombolytic activity |
| WO2007086069A1 (en) | 2006-01-27 | 2007-08-02 | Rappaport Family Institute For Research In The Medical Sciences | Methods and kits for determining blood coagulation |
| EP2596807B1 (en) | 2006-03-08 | 2015-12-16 | Archemix LLC | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| KR20120105405A (ko) * | 2009-06-23 | 2012-09-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 단백질에 결합하는 이중특이적 항체 |
| WO2011006982A2 (en) | 2009-07-17 | 2011-01-20 | Rigshospitalet | Inhibitors of complement activation |
| AU2010306581B2 (en) | 2009-10-16 | 2015-03-19 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
| EP2496259B1 (en) * | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria |
| CA2791962A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating degos' disease |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN107638565B (zh) | 2011-04-08 | 2021-12-21 | 莱斯特大学 | 用于治疗与masp-2依赖性补体活化相关的状况的方法 |
| MX361175B (es) | 2011-05-04 | 2018-11-29 | Omeros Corp | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
| EP2861246B1 (en) | 2012-06-18 | 2021-01-20 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| RS61351B1 (sr) | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| EA201891132A1 (ru) | 2015-11-09 | 2018-10-31 | Омерос Корпорейшн | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
| EA202191185A1 (ru) * | 2016-03-31 | 2021-10-29 | Омерос Корпорейшн | Способы ингибирования ангиогенеза у пациента |
| JPWO2018070521A1 (ja) * | 2016-10-14 | 2019-08-15 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Ceased
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active Active
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Ceased
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko not_active Ceased
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active Active
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active Active
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en not_active Ceased
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/en active
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 CA CA3076975A patent/CA3076975C/en active Active
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 CA CA3237802A patent/CA3237802A1/en active Pending
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 MX MX2018005314A patent/MX381987B/es unknown
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en not_active Abandoned
-
2025
- 2025-05-21 US US19/214,532 patent/US20260062498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| JP2023544834A5 (OSRAM) | ||
| EA201190326A8 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| JP2017528419A5 (OSRAM) | ||
| JP2015212284A5 (OSRAM) | ||
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| CY1116099T1 (el) | Πρωτεϊνη συντηξης κατα του καρκινου | |
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| EA201590543A1 (ru) | Основанные на фибронектине каркасные доменные белки, которые связываются с миостатином | |
| CY1117710T1 (el) | Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων | |
| MX379069B (es) | Vacunas terapeuticas contra el vph16. | |
| WO2009108261A3 (en) | Compositions and methods for the treatment of viral infections | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| IN2014CN00414A (OSRAM) | ||
| EA200870237A1 (ru) | Последовательности пептидов и композиции | |
| ATE539089T1 (de) | Cyclische rezeptor-assoziierte-proteine (rap)- peptide | |
| JP2019500414A5 (OSRAM) | ||
| EA201491277A1 (ru) | Противораковый слитый белок | |
| JP2018538356A5 (OSRAM) | ||
| EP4481045A3 (en) | Dna-binding protein using ppr motif, and use thereof | |
| ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof |